TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Anthony Partridge, PhD
Senior Principal Scientist, Early Discovery Pharmacology at Merck, Sharp & Dohme


Dr. Anthony Partridge is a Senior Principal Scientist at MSD Singapore where he leads programs in the early discovery space.  Previously, he was Senior Director of Biology at Pharmaron Beijing where he led a team focused on assay development/validation, screening, and built a world-class compound management facility.  As an In Vitro Pharmacology Capability Lead at Merck, he pioneered collaborative efforts with pharmacology-based CRO partners. Prior to this, he was a Senior Scientist in the Pharmacology group at Merck Montreal.  Dr. Partridge began his industry based career at Élan Pharmaceuticals in San Francisco.

Dr. Partridge has authored over twenty peer-reviewed scientific publications in top journals such as Cell, J. Clin. Invest., and JBC. He received his B.Sc. from the University of Guelph (1998), his Ph.D. from the University of Toronto (2003) and completed post-doctoral training at Scripps/UCSD (2003-2006).

Anthony Partridge, PhD's Network

Agenda Sessions

  • Chairperson's Remarks

    , 14:25
  • Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs – A Novel Approach with Broad Therapeutic Potential

    , 14:30
  • Chairperson's Remarks

    , 16:25